New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

ETF IssuersTemaCANC
CANC

Tema Oncology ETF

The CANC Exchange Traded Fund (ETF) is provided by Tema. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

$40.30
-$0.61 (-1.48%) yesterday
1:30 PM 07/20/26 Closed
1D price range
$40.30$41.49
52W price range
$25.23$42.38
YTD Perf.
+18.24%
YTD Flows
Annualized volatility
Fund AuM
€171M
Share class AuM
€171M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US87975E7013
TER
0.99%
Inception date
8/15/2023
Issuer
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Jul 17, 2026
0%5%10%15%20%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 05/31/26
Healthcare
98.38%
Unavailable
1.62%
Latest CANC news

No content available for this fund

FAQ about CANC

CANC is a Active ETF. This ETF provides exposure to Other Equities.
CANC carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.
CANC was introduced to the market on August 15, 2023. It trades on United States
Tema Oncology ETF, CANC, is provided by Tema. Learn more about Tema here.
CANC oversees €171M in assets as of July 17, 2026.
CANC follows a distributing dividend policy, meaning it pays out income to investors. As of July 17, 2026, its 12-month trailing yield was 0.05%.
As of May 31, 2026, CANC has significant geographic allocations in USA, Switzerland and United Kingdom.
As of May 31, 2026, CANC focuses largely on Healthcare.
As of May 31, 2026, CANC holds 54 positions in its portfolio, with 57.36% of assets concentrated in its top 15 holdings.
As of May 31, 2026, CANC top three holdings include Revolution Medicines, Inc., Eli Lilly & Co. and Roche Holding AG.
The base currency of CANC is USD.
Data as of 05/31/26
Revolution Medicines, Inc.
7.61%
Eli Lilly & Co.
4.65%
Roche Holding AG
4.23%
Novartis AG
4.03%
Cogent Biosciences, Inc.
3.98%
Immunome, Inc.
3.93%
Celcuity, Inc.
3.62%
Merck & Co., Inc.
3.60%
AstraZeneca PLC
3.57%
Bristol Myers Squibb Co.
3.35%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight